Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1Phase 1 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 2760Carcinoma, Non-Small-Cell Lung 2260Prostatic Neoplasms 1425Colorectal Neoplasms 1290Neoplasms 1258Multiple Myeloma 1084Lung Neoplasms 1048Neoplasm Metastasis 994Leukemia, Myeloid, Acute 984Lymphoma 900Melanoma 862Pancreatic Neoplasms 818Ovarian Neoplasms 805Carcinoma, Hepatocellular 782Stomach Neoplasms 753Recurrence 750Leukemia 733Lymphoma, Non-Hodgkin 684Leukemia, Lymphocytic, Chronic, B-Cell 665Lymphoma, Large B-Cell, Diffuse 616Squamous Cell Carcinoma of Head and Neck 615Precursor Cell Lymphoblastic Leukemia-Lymphoma 605Head and Neck Neoplasms 596Brain Neoplasms 592Carcinoma, Renal Cell 586Glioblastoma 572Rectal Neoplasms 563Myelodysplastic Syndromes 522Sarcoma 521Lymphoma, Follicular 516

Interventions

N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 2dalpiciclib 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × HR+/HER2- Advanced Breast Cancer × Clear all
NCT06556862 2025-08-13

Exploration of Dalpiciclib Plus HDACi in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor

Beijing 302 Hospital

Phase 2 Not yet recruiting
155 enrolled
Breast

HR+/HER2- Advanced Breast Cancer

NCT05983107 2023-08-09

Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast Cancer

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Recruiting
102 enrolled
Breast

HR+/HER2- Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡